Bio-Works Investor Relations

Announcements of shareholder meetings, documents and financial calendar

First North Disclaimer

First North is an alternative marketplace operated by an exchange within the NASDAQ OMX group. Companies on First North are not subject to the same rules as companies on the regulated main market. Instead they are subject to a less extensive set of rules and regulations adjusted to small growth companies. The risk in investing in a company on First North may therefore be higher than investing in a company on the main market. All companies with shares traded on First North have a Certified Adviser who monitors that the rules are followed. The Exchange approves the application for admission to trading.

Annual General Meeting (AGM) / Årsstämma

I och med Covid-19 så har Bio-Works Technologies AB’s styrelse beslutat att möjliggöra för bolagets aktieägare att delta elektroniskt via en live broadcast. Regelverket stipulerar att röstberättigad måste delta fysiskt på stämman för att kunna rösta och därför har styrelsen beslutat att poströstning skall erbjudas de aktieägare som inte kan närvara fysiskt på stämman.

För att utnyttja möjligheten till poströstning ska aktieägaren använda det formulär för poströstning som finns nedan. Anmälning sker sig till Bolaget senast måndagen den 11 maj 2020

Ifyllt och undertecknat poströstningsformulär ska skickas till Bio-Work Technologies, Virdings Allé 18, 754 50 Uppsala, eller till info@bio-works.com. Poströstningsformuläret ska vara Bio-Works Technologies tillhanda senast den 14 maj 2020.

Om aktieägaren är en juridisk person ska kopia av registreringsbevis, eller om sådan handling inte finns, motsvarande behörighetshandling bifogas. Aktieägaren får inte förse poströsten med särskilda instruktioner eller villkor. Om så sker är rösten ogiltig.

Ytterligare instruktioner finns i formuläret.

Formulär för poströstning inför Årsstämma 2020

Notice of annual general meeting May 15 2020

Notice Bio-Works Technologies AGM 2020 Kallelse Årsstämma 2020

Power of attorney AGM 2020

Power of attorney Fullmakt

Protokoll/Minutes Bio-Works Technologies AGM 2020

Protokoll/Minutes Bio-Works Technologies AGM 2020

A video of the AGM is available

Watch the video here

Peter von Ehrenheim

Operative background from Pharmacia Biotech, Amersham and GE Healthcare. General manager for Separations Division 1999-2006. From 2006-2011 General manager for GE’s Life Sciences Business which was recently acquired by Danaher. From 2011 entrepreneur with different companies and board roles. Presently chairman in Medcap AB, Boule Diagnostics AB and Sophion A/S. Also Director in Biotage AB.

Education: M.Sc. in Mechanical Engineering

Shares: 602,905 (via Färjsundet AB)

Thomas Eklund

Independent advisor, board member and investor. Head of Investor Growth Capital 2001 to 2013. Board member and lead investor in Swedish Orphan, Carmel Pharma, Entific Medical, Vardapoteket and Memira. Previously Investment Director at AAC Capital and Director Handelsbanken Market, corporate finance. Presently chairman in Biotage AB and Sedana Medical AB and director in Boule Diagnostics, Immedica Pharma AB, Swedencare AB and Surgical Science AB. Advisor to Impilo AB and Investor AB.

Education: MBA Stockholm School of Economics

Shares: 555.556

Notice of extra shareholders meeting 2019-09-09

Notice Bio-Works Technologies EGM 2019 Kallelse extra bolagsstämma 2019

The following persons are proposed for election to the Board of Directors

Peter von Ehrenheim

Operative background from Pharmacia Biotech, Amersham and GE Healthcare. General manager for Separations Division 1999-2006. From 2006-2011 General manager for GE’s Life Sciences Business which was recently acquired by Danaher. From 2011 entrepreneur with different companies and board roles. Presently chairman in Medcap AB, Boule Diagnostics AB and Sophion A/S. Also Director in Biotage AB.

Education: M.Sc. in Mechanical Engineering

Shares: 602,905 (via Färjsundet AB)

Thomas Eklund

Independent advisor, board member and investor. Head of Investor Growth Capital 2001 to 2013. Board member and lead investor in Swedish Orphan, Carmel Pharma, Entific Medical, Vardapoteket and Memira. Previously Investment Director at AAC Capital and Director Handelsbanken Market, corporate finance. Presently chairman in Biotage AB and Sedana Medical AB and director in Boule Diagnostics, Immedica Pharma AB, Swedencare AB and Surgical Science AB. Advisor to Impilo AB and Investor AB.

Education: MBA Stockholm School of Economics

Shares: 555.556

Power of attorney

Power of attorney Fullmakt

Protokoll extra bolagsstämma

Protokoll Bio-Works Technologies EGM 2019

Notice of extra shareholders meeting 2019-06-12

Notice of extra shareholders meeting Bio-Works technologies June 2019 Kallelse till extra bolagsstämma i Bio-Works Technologies juni 2019

Power of attorney

Power of attorney extra shareholders meeting June 2019 Fullmakt extra bolagsstämma juni 2019

Documents related to the EGM

Styrelsens redogörelse Revisorns yttrande

Styrelsens beslut om riktad emission Styrelsens beslut on företrädesemission

Protokoll extra bolagsstämma

Protokoll extra bolagsstämma 2019-06-12

Peter von Ehrenheim

Operative background from Pharmacia Biotech, Amersham and GE Healthcare. General manager for Separations Division 1999-2006. From 2006-2011 General manager for GE’s Life Sciences Business which was recently acquired by Danaher. From 2011 entrepreneur with different companies and board roles. Presently chairman in Medcap AB, Boule Diagnostics AB and Sophion A/S. Also Director in Biotage AB.

Education: M.Sc. in Mechanical Engineering

Shares: 602,905 (via Färjsundet AB)

Thomas Eklund

Independent advisor, board member and investor. Head of Investor Growth Capital 2001 to 2013. Board member and lead investor in Swedish Orphan, Carmel Pharma, Entific Medical, Vardapoteket and Memira. Previously Investment Director at AAC Capital and Director Handelsbanken Market, corporate finance. Presently chairman in Biotage AB and Sedana Medical AB and director in Boule Diagnostics, Immedica Pharma AB, Swedencare AB and Surgical Science AB. Advisor to Impilo AB and Investor AB.

Education: MBA Stockholm School of Economics

Shares: 555.556

Election committee for the board, in preparation for the Annual Shareholders Meeting 2019:

  • Thomas Pollare, representing Amicogen
  • Daniel Sandberg
  • Andy Bright

Notice of annual general meeting (AGM) 2019

Notice of Bio-Works Technologies AGM 2019 Kallelse Bio-Works Technologies årsstämma 2019

Power of attorney

Power of attorney Bio-Works Technologies AGM 2019 Fullmaktsformulär Bio-Works Technologies AGM 2019

Årsredovisning 2018 inkl. revisionsberättelse

Årsredovisning 2018 inkl. revisionsberättelse

Protokoll från årsmöte 2019-05-17

Protokoll årsmöte 2019-05-17

The share

Share: Bio-Works Technologies AB
Ticker: BIOWKS
ISIN code: SE0007387089
Share capital: 3 041 575 SEK
Number of shares: 30 415 746

Rights issue June 2019

Bio-Works announces a new share issue in Bio-Works Technologies AB issued with preferential rights for existing shareholders.

Prospectus 2017 / Initial Public Offering (IPO) (Swedish)

Bio-Works Technologies AB plans listing on Nasdaq First North in December 14th

Major shareholders per 31 March 2020

Last updated 2020-02-14
Shareholder: Number of shares: Share capital & votes (%)
Nortal Investments AB 4 019 885 13,22
Amicogen Inc. 3 007 896 9,89
Nordnet Pensionsförsäkring AB 1 400 697 4,92
Försäkringsaktiebolaget Avanza Pension 1 375 316 4,52
Skandinaviska Enskilda Banken AB 974 228 3,20
Other shareholders 19 637 724 64,56
Total shares 30 415 746 100,00

Financial Calendar

2020-05-15 | AGM 2019

kl. 10:00

2020-08-21 | Quarterly report, Q2 2020

kl. 13:00

2020-10-23 | Quarterly report, Q3 2020

kl. 13:00

2021-02-19 | Quarterly report, Q4 2020

kl. 13:00

Corporate Governance

Click to expand

Bolagsordning för bio-works Technologies AB

The articles of association for Bio-Works Technologies

(556935-3559)

The English text is a translation of the Swedish text. In the event of discrepancies between the provisions of the English translation to Swedish version, the Swedish version shall prevail.

1. FIRMA / CORPORATE NAME
Bolagets firma är Bio-Works Technologies AB. Bolaget är publikt (publ).

The registered name of the company is Bio-Works Technologies AB. The company is a public company (publ).

2. STYRELSENS SÄTE / DOMICILE
Styrelsen ska ha sitt säte i Uppsala kommun, Uppsala län.

The registered office of the board of directors is the municipality of Uppsala, Uppsala County.

3. VERKSAMHET / BUSINESS
Föremålet för bolagets verksamhet är att utveckla, tillverka, marknadsföra och sälja absorbenter riktat till life science-, livsmedels och miljösektorerna samt idka därmed förenlig verksamhet.

The object of the company’s business is to develop, manufacture, market and sell absorbents to the life science, food and beverage and environmental business areas, as well as to conduct any other activities compatible therewith.

4. AKTIEKAPITAL / SHARE CAPITAL
Aktiekapitalet ska vara lägst 1 200 000 kronor och högst 4 800 000 kronor.

The share capital shall be not less than SEK 1,200,000 and not more than SEK 4,800,000.

5. ANTAL AKTIER / NUMBER OF SHARES
Antalet aktier ska vara lägst 12 000 000 och högst 48 000 000.

The number of shares shall not be fewer than 12 000 000 and not more than 48 000 000.

6. STYRELSEN / BOARD OF DIRECTORS
Styrelsen ska bestå av lägst tre och högst tio ledamöter med högst tio suppleanter. Ledamöterna och suppleanterna väljs på bolagsstämman för tiden intill slutet av nästa årsstämma.

The board of directors shall consist of no less than three and no more than ten members with a maximum of ten deputy members. The board of directors and the deputy members are elected at the shareholders’ meeting for the period extending to the close of the next annual shareholders’ meeting.

7. REVISOR / AUDITOR
Bolaget ska ha en eller två revisorer samt högst en revisorssuppleant. Till revisor samt, i förekommande fall, revisorssuppleant ska utses auktoriserad revisor eller ett registrerat revisionsbolag.

The company shall have one or two auditors with no more than one deputy auditor. An authorised auditor or a registered accounting firm shall be elected as auditor and, when applicable, deputy auditor.

8. KALLELSE / NOTICE
Kallelse till bolagsstämma ska ske genom annonsering i Post- och Inrikes Tidningar samt genom att kallelsen hålls tillgänglig på bolagets webbplats. Att kallelse har skett ska annonseras i Dagens Industri.
För att få delta i bolagsstämman ska aktieägare dels vara upptagen i utskrift eller annan framställning av hela aktieboken avseende förhållandena fem vardagar före stämman, dels göra anmälan till bolaget senast den dag som anges i kallelsen till stämman. Sistnämnda dag får inte vara söndag, annan allmän helgdag, lördag, midsommarafton, julafton eller nyårsafton och får inte infalla tidigare än femte vardagen före stämman.

Notice of a shareholders’ meeting shall be announced in Post- och Inrikes Tidningar (the Swedish Official Gazette) and by making the notice available on the company’s website. An announcement with information that the notice has been issued shall be published in Dagens Industri.
To participate at a shareholders’ meeting, shareholders shall, firstly be recorded in a printout or other presentation of the share register relating to the circumstances five working days prior to the shareholders’ meeting, and secondly notify the company no later than the day stipulated in the notice convening the meeting. The latter mentioned day may not be a Sunday, any other public holiday, a Saturday, Midsummer’s Eve, Christmas Eve or New Year’s Eve, and must not be more than the fifth working day prior to the meeting.

9. ÅRSSTÄMMA /ANNUAL GENERAL MEETING
Bolagsstämma ska hållas på den ort där styrelsen har sitt säte, eller i Stockholm efter beslut av styrelsen.
På årsstämma ska följande ärenden förekomma till behandling:
1. Val av ordförande vid stämman
2. Upprättande och godkännande av röstlängd
3. Godkännande av dagordningen
4. Val av en eller två justeringsmän
5. Prövning av om stämman blivit behörigen sammankallad
6. Framläggande av årsredovisningen och revisionsberättelsen samt koncernredovisning och koncernrevisionsberättelse
7. Beslut om
a) fastställande av resultaträkningen och balansräkningen samt, i förekommande fall, koncernresultaträkningen och koncernbalansräkningen
b) dispositioner beträffande bolagets vinst eller förlust enligt den fastställda balansräkningen
c) ansvarsfrihet åt styrelseledamöter och verkställande direktör
8. Fastställande av antalet styrelseledamöter och styrelsesuppleanter samt revisorer och revisorssuppleant, som ska utses av stämman
9. Fastställande av arvoden till styrelsen och revisorer
10. Val av styrelseledamöter och styrelsesuppleanter samt revisorer och revisorssuppleant
11. Annat ärende, som ankommer på stämman enligt aktiebolagslagen (2005:551)

A shareholders’ meeting shall be held at the place where the board of directors has its registered office or in Stockholm after a resolution taken by the board of directors.
The following matters shall be addressed at the annual shareholders’ meeting:
1. Election of chairman of the meeting
2. Preparation and approval of the voting list
3. Approval of the agenda
4. Election of one or two persons to approve the minutes
5. Determination of whether the meeting was duly convened
6. Presentation of the annual report and the auditor’s report as well as the consolidated annual report and the consolidated auditor’s report
7. Resolutions regarding:
a) adoption of the income statement and the balance sheet, as well as, where applicable, consolidated annual report and the consolidated auditor’s report
b) allocation of the company’s profits or losses pursuant to the adopted balance sheet
c) discharge of personal liability of the board members and, where applicable, the managing director
8. Determination of the number of board of directors and deputy members as well as auditors and deputy auditor to be elected by the shareholders’ meeting
9. Determination of fees to be paid to the board of directors and auditors
10. Election of members of the board of directors and deputy members as well as auditors and deputy auditor.
11. Any other matter on which the annual general meeting is required to resolve pursuant to the Swedish Companies Act (2005:551)

10. RÄKENSKAPSÅR / FINANCIAL YEAR
Bolagets räkenskapsår ska vara kalenderår.

The company’s financial year shall be calendar year.

11. AVSTÄMNINGSFÖRBEHÅLL / CENTRAL SECURITIES DEPOSITORY CLAUSE
Bolagets aktier ska vara registrerade i ett avstämningsregister enligt lagen (1998:1479) om värdepapperscentraler och kontoföring av finansiella instrument.

The shares of the company shall be registered in a central securities depository register according to the Swedish Financial Instruments Accounts Act (1998:1479).

Contact – Investor Relations

Investor Relations

Mats Johnson

Chief Executive Officier, Bio-Works Technologies
Phone: +46 705 165337
Email: Mats.johnson@bio-works.com

Certified adviser

FNCA Sweden AB

Certified adviser, Bio-Works Technologies
Phone: +46 8 528 00 399
Email: info@fnca.se
Webpage: www.fnca.se

Copyrights © 2020 All Rights Reserved by Bio-Works.